Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Gene Panel Predicts Likelihood of Favorable Response by Multiple Myeloma Patients to Selinexor Treatment

By LabMedica International staff writers
Posted on 16 Jun 2022

A novel three-gene expression signature has been identified that can be used to predict the response of multiple myeloma (MM) patients to the chemotherapeutic drug selinexor.

Selinexor is a selective inhibitor of nuclear export used as an anti-cancer medication. It works by blocking the action of exportin 1 and thus preventing the transport of several proteins involved in cancer-cell growth from the cell nucleus to the cytoplasm, which ultimately arrests the cell cycle and leads to apoptosis.

The most common side effects of selinexor treatment include nausea, vomiting, decreased appetite, weight loss, diarrhea, tiredness, thrombocytopenia (low blood-platelet counts), anemia, low levels of white blood cells, and hyponatraemia (low blood sodium levels). Due to these relatively severe side effects, it is important to identify patients who will respond positively and, thereby, potentially expand the use of the drug. However, there currently are no known genomic biomarkers or assays to help select MM patients at higher likelihood of favorable response to selinexor.

Investigators at the Mount Sinai School of Medicine (New York, NY, USA) sought to discover relevant biomarkers by performing RNA sequencing, differential gene expression, and pathway analysis on CD138+ cells from the bone marrow of 100 patients with MM. The three-gene signature (WNT10A, DUSP1, and ETV7) identified in the first part of the study was validated in 64 patients from the Selinexor Treatment of Refractory Myeloma (STORM) cohort of triple-class refractory MM and additionally in an external cohort of 35 patients treated in a real-world setting outside of clinical trials.

Results revealed that the three-gene signature correlated with both depth and duration of response to selinexor in MM, and that it also was validated in a different tumor type using a cohort of pre-treatment tumors from patients with recurrent glioblastoma.

Senior author Dr. Samir Parekh, professor of medicine, hematology, and medical oncology at the Mount Sinai School of Medicine, said, “Our findings provide the basis for improving patient selection for targeted agents using a small panel of genes to guide precise application of these drugs in real world scenarios, including relapse following CAR-T, an increasingly important clinical challenge in myeloma.”

The study was published in the June 15, 2022, online edition of the journal JCO Precision Oncology.


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunofluorescence Analyzer
MPQuanti
New
Biological Indicator Vials
BI-O.K.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.